GHRH Peptide Antagonist Shows Antidepressant and Anti-Anxiety Effects in Mice
The GHRH antagonist MIA-602 produced anxiolytic and antidepressant-like effects in mice over 4 weeks by reducing brain inflammation and oxidative stress through Nrf2 and BDNF pathways.
Quick Facts
What This Study Found
GHRH antagonist MIA-602 produced anxiolytic and antidepressant effects in mice after 4 weeks of subcutaneous treatment, mediated through Nrf2 and BDNF signaling in the hippocampus and prefrontal cortex.
Key Numbers
4 weeks subcutaneous treatment; increased Nrf2 and BDNF in hippocampus and prefrontal cortex; anti-inflammatory and antioxidant effects confirmed
How They Did This
Animal study in adult mice. MIA-602 was given subcutaneously for 4 weeks. Tested anxiety and depression-like behaviors using standard behavioral tests. Measured inflammatory markers, oxidative stress, Nrf2, and BDNF in brain tissue.
Why This Research Matters
Current antidepressants and anti-anxiety drugs do not work for everyone and can have significant side effects. GHRH antagonists represent a completely different approach that targets inflammation and oxidative stress rather than serotonin or other traditional pathways.
The Bigger Picture
GHRH antagonists were originally developed as anti-cancer agents (as seen in another study by Schally's group). The discovery that they also have anxiolytic and antidepressant properties represents a surprising and potentially transformative finding. If GHRH peptide antagonists can treat mood disorders through anti-inflammatory and neuroprotective mechanisms, they would represent an entirely new class of psychiatric medication — one targeting the inflammation-mental illness connection rather than the monoamine pathways of current drugs.
What This Study Doesn't Tell Us
Animal study only. Mouse models of anxiety and depression do not fully replicate human mood disorders. No comparison to existing antidepressant or anti-anxiety drugs. Long-term effects and safety are unknown.
Questions This Raises
- ?Would MIA-602 be effective in human PTSD or treatment-resistant depression where inflammation is a known factor?
- ?How do the anxiolytic effects of GHRH antagonists compare to existing benzodiazepines or SSRIs in strength and onset?
- ?Could GHRH antagonists be used as adjuncts to existing psychiatric medications for enhanced efficacy?
Trust & Context
- Key Stat:
- New mechanism: inflammation → mood MIA-602 treats mood disorders through anti-inflammatory and antioxidant pathways (Nrf2, BDNF) rather than serotonin — a fundamentally different approach from existing antidepressants.
- Evidence Grade:
- This is a preclinical animal study using behavioral tests and brain tissue analysis in mice. While published in the high-impact journal Molecular Psychiatry, the findings require human clinical validation before any therapeutic conclusions.
- Study Age:
- Published in 2021, this study was part of the emerging research connecting GHRH peptide antagonists to neuropsychiatric applications. Published in Molecular Psychiatry (high impact factor), it signals serious academic interest in this approach.
- Original Title:
- Effects of growth hormone-releasing hormone receptor antagonist MIA-602 in mice with emotional disorders: a potential treatment for PTSD.
- Published In:
- Molecular psychiatry, 26(12), 7465-7474 (2021)
- Authors:
- Recinella, Lucia(5), Chiavaroli, Annalisa(5), Orlando, Giustino(5), Ferrante, Claudio, Veschi, Serena, Cama, Alessandro, Marconi, Guya Diletta, Diomede, Francesca, Gesmundo, Iacopo, Granata, Riccarda, Cai, Renzhi, Sha, Wei, Schally, Andrew V, Brunetti, Luigi, Leone, Sheila
- Database ID:
- RPEP-05714
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
How is GHRH antagonist different from regular antidepressants?
Traditional antidepressants (SSRIs, SNRIs) work by changing serotonin and norepinephrine levels in the brain. MIA-602 works through a completely different mechanism — it reduces brain inflammation and oxidative stress while boosting BDNF, a protein that helps brain cells grow and form new connections. This addresses the inflammation-depression link that current drugs don't specifically target.
Could this help with PTSD?
The researchers believe so. PTSD is strongly linked to brain inflammation and oxidative stress — exactly the processes that MIA-602 modulates. The anti-anxiety effects demonstrated in this mouse study, combined with the drug's anti-inflammatory mechanism, make it a promising candidate for PTSD treatment. However, human clinical trials are needed to confirm this potential.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05714APA
Recinella, Lucia; Chiavaroli, Annalisa; Orlando, Giustino; Ferrante, Claudio; Veschi, Serena; Cama, Alessandro; Marconi, Guya Diletta; Diomede, Francesca; Gesmundo, Iacopo; Granata, Riccarda; Cai, Renzhi; Sha, Wei; Schally, Andrew V; Brunetti, Luigi; Leone, Sheila. (2021). Effects of growth hormone-releasing hormone receptor antagonist MIA-602 in mice with emotional disorders: a potential treatment for PTSD.. Molecular psychiatry, 26(12), 7465-7474. https://doi.org/10.1038/s41380-021-01228-5
MLA
Recinella, Lucia, et al. "Effects of growth hormone-releasing hormone receptor antagonist MIA-602 in mice with emotional disorders: a potential treatment for PTSD.." Molecular psychiatry, 2021. https://doi.org/10.1038/s41380-021-01228-5
RethinkPeptides
RethinkPeptides Research Database. "Effects of growth hormone-releasing hormone receptor antagon..." RPEP-05714. Retrieved from https://rethinkpeptides.com/research/recinella-2021-effects-of-growth-hormonereleasing
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.